Skip to main content

Advertisement

Table 1 Patients’ clinical characteristics by cTACE and DEB-TACE groups. (N = 273)

From: Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Variables Total (N = 273) cTACE (n = 201) DEB-TACE (n = 72) p-value
Age, years 64.4 ± 10.7 65.3 ± 10.7 61.7 ± 10.3 0.009
Sex
 Female 86 (31.5) 63 (31.3) 23 (31.9) 0.925
 Male 187 (68.5) 138 (68.7) 49 (68.1)  
Previous treatment
 None 172 (63.0) 126 (62.7) 46 (63.9) 0.166
 Operation 53 (19.4) 35 (17.4) 18 (25.0)  
 Locoregional treatment 41 (15.0) 33 (16.4) 8 (11.1)  
 Operation + locoregional 7 (2.6) 7 (3.5) 0 (0)  
Uni-/Bi-lobar
 Unilobar 136 (49.8) 106 (52.7) 30 (41.7) 0.107
 Bilobar 137 (50.2) 95 (47.3) 42 (58.3)  
HBV/HCV
 Non-B or C 22 (8.1) 18 (9.0) 4 (5.6) 0.225
 HBV 127 (46.5) 87 (43.3) 40 (55.6)  
 HCV 108 (39.6) 82 (40.8) 26 (36.1)  
 HBV + HCV 16 (5.9) 14 (7.0) 2 (2.8)  
GOT (IU/L) 70.63 ± 48.72 69.88 ± 50.4 70.63 ± 48.72 0.331
GOT
 Not normal 156 (57.1) 112 (55.7) 44 (61.1) 0.428
 Normal 117 (42.9) 89 (44.3) 28 (38.9)  
GPT (IU/L) 72.08 ± 80.27 69.97 ± 81.77 72.08 ± 80.27 0.109
GPT
 Not normal 132 (48.4) 91 (45.3) 41 (56.9) 0.089
 Normal 141 (51.6) 110 (54.7) 31 (43.1)  
Bilirubin (mg/dL) 0.76 ± 0.44 0.73 ± 0.42 0.76 ± 0.44 0.087
Bilirubin
 Not normal 22 (8.1) 13 (6.5) 9 (12.5) 0.107
 Normal 251 (91.9) 188 (93.5) 63 (87.5)  
AFP (ng/mL) 875.28 ± 4510.43 766.21 ± 4607.3 875.28 ± 4510.43 0.497
AFP
 Negative 224 (82.1) 169 (84.1) 55 (76.4) 0.145
 Positive 49 (17.9) 32 (15.9) 17 (23.6)  
Albumin (g/dL) 4 ± 0.49 3.98 ± 0.48 4 ± 0.49 0.312
Albumin
 Not normal 41 (15.0) 29 (14.4) 12 (16.7) 0.648
 Normal 232 (85.0) 172 (85.6) 60 (83.3)  
Ascites
 None 257 (94.1) 191 (95.0) 66 (91.7) 0.432
 Mild 15 (5.5) 9 (4.5) 6 (8.3)  
 Moderate 1 (0.4) 1 (0.5) 0 (0)  
Child-Pugh stage
 5 219 (80.2) 161 (80.1) 58 (80.6) 0.883
 6 44 (16.1) 33 (16.4) 11 (15.3)  
 7 9 (3.3) 6 (3.0) 3 (4.1)  
 8 1 (0.4) 1 (0.5) 0 (0)  
ECOG stage
 0 271 (99.3) 199 (99.0) 72 (100) 1.000
 1 2 (0.7) 2 (1.0) 0 (0)  
CLIP stage
 0 40 (14.7) 32 (15.9) 8 (11.1) 0.018
 1 172 (63.0) 132 (65.7) 40 (55.6)  
 2 49 (17.9) 29 (14.4) 20 (27.8)  
 3 10 (3.7) 8 (4.0) 2 (2.8)  
 4 2 (0.7) 0 (0) 2 (2.8)  
Okuda stage
 0 250 (91.6) 185 (92.0) 65 (90.3) 0.471
 1 20 (7.3) 13 (6.5) 7 (9.7)  
 2 3 (1.1) 3 (1.5) 0 (0)  
BCLC stage
 A 87 (32) 71 (35.7) 16 (22.2) 0.040
 B + C 184 (67.9) 128 (64.3) 56 (77.8)  
Largest target (cm) 3.64 ± 2.59 3.47 ± 2.32 4.12 ± 3.20 0.175
Tumor numbers 3.5 ± 1.9 3.4 ± 1.9 3.6 ± 2.0 0.690
 Tumor numbers ≤5 197 (72.2) 148 (73.6) 49 (68.1) 0.365
 Tumor numbers > 5 76 (27.8) 53 (26.4) 23 (31.9)  
Sum of the largest five hepatocellular carcinoma diameter (cm) 6.64 ± 2.33 6.63 ± 2.26 6.66 ± 2.53 0.908
  1. Aspartate aminotransferase (GOT), Alanine aminotransferase (GPT)
  2. Data are summarized as mean ± SD and n (%) for continuous and categorical variables by treatment. Differences between treatments were compared using Mann-Whitney U test for continuous variables and Chi-square test / or Fisher’s exact test for categorical variables
  3. Bold p-values indicate statistical significance (p < 0.05)